<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Functional movement disorders
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Functional movement disorders
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Functional movement disorders
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarah C Lidstone, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1944642068">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional movement disorder (FMD) is a subtype of functional neurological symptom disorder (conversion disorder) in which the primary manifestation is tremor, dystonia, gait disorder, or other abnormal movement. Patients with FMD have neurologic symptoms that are incongruent with known neurologic disease but are nevertheless genuine and cause distress and/or psychosocial impairment [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         FMD is common in clinical settings, but the diagnosis is often delayed or missed, and prognosis for complete remission is generally poor. Over time, more emphasis has been placed on physical examination signs to guide diagnosis and use of evidence-based treatments, including physiotherapy and multidisciplinary rehabilitation.
        </p>
        <p>
         This topic reviews the epidemiology, etiology and pathogenesis, clinical features, diagnosis, treatment, and prognosis of FMD. Functional neurological symptom disorder more broadly, as well as other subtypes (eg, functional weakness and nonepileptic seizures), are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85764.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Epidemiology, pathogenesis, and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85765.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Clinical features, assessment, and comorbidity"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2227.html" rel="external">
          "Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131655.html" rel="external">
          "Psychogenic nonepileptic seizures: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2846423155">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         FMD is a subtype of functional neurological symptom disorder (conversion disorder)  (
         <a class="graphic graphic_table graphicRef91102" href="/z/d/graphic/91102.html" rel="external">
          table 1
         </a>
         ). Older terms, including psychogenic, hysterical, and nonorganic, have fallen out of favor [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14826.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Terminology, diagnosis, and differential diagnosis"
         </a>
         .)
        </p>
        <p>
         Subtypes of functional neurological symptom disorder recognized by DSM-5 include (from most to least common):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonepileptic seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weakness and paralysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal movement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Speech symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Globus sensation (swallowing symptoms)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensory symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive symptoms
        </p>
        <p>
        </p>
        <p>
         The International Classification of Diseases, 11
         <sup>
          th
         </sup>
         Revision (ICD-11) uses the term "dissociative neurological symptom disorder" for the DSM-5 diagnosis of functional neurological symptom disorder [
         <a href="#rid3">
          3
         </a>
         ]. Older versions used the term "dissociative disorders." (See
         <a class="medical medical_review" href="/z/d/html/14826.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Terminology, diagnosis, and differential diagnosis", section on 'International Classification of Diseases, 11th Revision'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3134431412">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Population rates of FMD are not known, and most studies are small and drawn from clinical settings focusing on specific phenotypes. The incidence of functional neurological symptom disorder more broadly is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/85764.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Epidemiology, pathogenesis, and prognosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence in clinical settings
         </strong>
         – FMD accounts for 2 to 10 percent of patients in movement disorder clinics [
         <a href="#rid4">
          4-7
         </a>
         ]. The prevalence of FMD among patients who present with dystonia and fixed, contracted joints may be even higher. As an example, one prospective study of 41 such patients reported that criteria for functional dystonia were fulfilled in 15 (37 percent) [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Functional dystonia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age of onset
         </strong>
         – FMD usually begins in middle adulthood but can affect children as young as six years and older adults [
         <a href="#rid6">
          6,9-11
         </a>
         ]. The mean age at presentation is 40 years [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex ratio
         </strong>
         – Females are affected more often than males in both children and adults. In large cohort studies, the percentage of females ranges from 60 to 90 percent [
         <a href="#rid12">
          12-15
         </a>
         ]. However, the sex preponderance may vary by phenotype; as an example, functional myoclonus and functional parkinsonism appear to have similar frequency in males and females [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenotype frequency
         </strong>
         – Functional tremor is the most frequent FMD phenotype, followed by functional dystonia [
         <a href="#rid9">
          9,15-19
         </a>
         ]. Approximately one-quarter of patients have a mixed phenotype. A meta-analysis that included nearly 5000 cases of FMD reported the following phenotype frequencies: mixed FMD (23 percent), tremor (22 percent), weakness (18 percent), dystonia (12 percent), gait disorder (8 percent), myoclonus/jerks (5 percent), and parkinsonism (2 percent) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2437471675">
         <span class="h1">
          ETIOLOGIC FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FMD, like other functional neurological symptom disorders, is best conceptualized using a biopsychosocial model of predisposing, precipitating, and perpetuating factors. Factors can be biologic, psychological, or social, and the combination of factors is unique to each patient  (
         <a class="graphic graphic_table graphicRef88079" href="/z/d/graphic/88079.html" rel="external">
          table 2
         </a>
         ). None of the factors is individually causal; rather, their presence increases risk of developing the disorder.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Predisposing factors
         </strong>
         – Common risk factors for developing FMD include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Female sex
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Younger age
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emotional and personality disorders
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurologic disease/symptoms
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coexistence of other health issues
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Difficulties in interpersonal relationships
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychiatric illness
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Stressful life events and maltreatment are substantially more common in people with functional neurological symptom disorder than in unaffected controls [
         <a href="#rid21">
          21
         </a>
         ]. Emotional neglect is more common than traditionally emphasized sexual and physical abuse, but many patients report no stressors. Some studies have found higher rates of childhood trauma in patients with FMD compared with sex-matched controls, while others have not [
         <a href="#rid4">
          4,22-28
         </a>
         ]. Exposure to functional or organic movement disorders among friends and family (disease modeling) may also be a risk factor for developing FMD [
         <a href="#rid11">
          11,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is emerging evidence that genetic factors may act as predisposing factors and may interact with environmental factors such as childhood adverse events. A study of single-nucleotide polymorphisms from 14 candidate genes among patients with FMD identified a polymorphism of the tryptophan hydroxylase 2 (
         <em>
          TPH2
         </em>
         ) gene, which predicted younger age at symptom onset, interaction with childhood trauma resulting in greater symptom severity, and reduced connectivity between right amygdala and middle frontal gyrus [
         <a href="#rid30">
          30
         </a>
         ]. Additional factors, such as the nature and timing of stressful events, may influence their role as risk factors in adulthood. (See
         <a class="medical medical_review" href="/z/d/html/85764.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Epidemiology, pathogenesis, and prognosis", section on 'Predisposing, precipitating, and perpetuating factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precipitating factors
         </strong>
         – A precipitating factor occurring in close temporal proximity with symptom onset can be identified in 50 to 80 percent of patients with FMD. In some cases, symptoms of panic attack are present during the precipitating event [
         <a href="#rid27">
          27
         </a>
         ]. Examples of precipitating factors include [
         <a href="#rid27">
          27,31
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical injury or accident
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgery, medical procedure, or medical illness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emotional event
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurologic disorder (eg, severe migraine, brachial neuritis, Bell's palsy, vertigo, carpal tunnel syndrome)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perpetuating factors
         </strong>
         – Factors that, if present, may perpetuate FMD symptoms are important to identify, particularly those that are modifiable. Common perpetuating factors include [
         <a href="#rid28">
          28,32,33
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pain
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical deconditioning
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ongoing psychosocial stress related to family, work, or school
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Untreated anxiety
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intercurrent illness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Illness beliefs regarding an alternate diagnosis (may or may not be modifiable)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Comorbid psychiatric disorders
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disability-related financial benefits
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Litigation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Life stress that was relieved by onset of the disorder and would likely recur if the patient were to recover
        </p>
        <p>
        </p>
        <p>
         Cognitive-behavioral, neurobiologic, and psychodynamic hypotheses that attempt to explain how functional symptoms develop in the context of these factors are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/85764.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Epidemiology, pathogenesis, and prognosis", section on 'Etiologic hypotheses'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3632260974">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FMD is a complex neuropsychiatric condition, and underlying mechanisms are an intense area of study [
         <a href="#rid34">
          34
         </a>
         ]. Processes relevant to FMD include [
         <a href="#rid35">
          35-40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal self-directed attention
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal beliefs and expectations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal sense of agency (ie, a subjective sense of control) for self-generated movements
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor learning and plasticity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal limbic-motor interface
        </p>
        <p>
        </p>
        <p>
         Research has sought to understand the neural mechanisms by which functional movement symptoms emerge, using predictive coding models of how the brain generates a sense of agency [
         <a href="#rid41">
          41
         </a>
         ]. At their core, functional motor symptoms are experienced as involuntary, related to a loss of sense of agency due to mismatch between feedforward signals through the "agency network" (involving the right temporoparietal junction) and feedback sensory information once movement is executed. This mismatch arises due to overweighting of the feedforward message, which is strongly influenced by expectation, enhanced attention, and emotion [
         <a href="#rid36">
          36
         </a>
         ]. In other words, incoming afferent information is overwhelmed by "top-down" prior signals [
         <a href="#rid35">
          35,42
         </a>
         ]. In patients with alexithymia (difficulty identifying and expressing emotion) or a tendency to somatize, emotional or autonomic symptoms that occur with a triggering event may be misinterpreted as being caused by a physical illness [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Subtle structural and functional differences between individuals with FMD and controls have been demonstrated using advanced imaging techniques. As an example, an observational study using magnetic resonance imaging (MRI) voxel-based morphometry analysis showed increased gray matter volume in left amygdala, left striatum, left cerebellum, left fusiform gyrus, and bilateral thalamus and decreased volume of left sensorimotor cortex among 35 patients with FMD compared with 35 unaffected controls, irrespective of clinical phenomenology [
         <a href="#rid43">
          43
         </a>
         ]. However, other smaller studies have shown a different set of cerebral abnormalities, perhaps due to variations in methods of analysis. Similar work by the same group demonstrated impaired self-agency (the ability to control one's actions) using functional MRI, which showed a lack of connectivity between the right temporoparietal junction and sensorimotor cortex [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2324848640">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H2023970444">
         <span class="h2">
          Shared features
         </span>
         <span class="headingEndMark">
          —
         </span>
         FMD very often begins abruptly, regardless of phenotype  (
         <a class="graphic graphic_table graphicRef50039" href="/z/d/graphic/50039.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. In a cohort of 50 patients with FMD, 54 percent of patients reported sudden onset within seconds to minutes, while 36 percent developed symptoms over the course of hours to one day [
         <a href="#rid27">
          27
         </a>
         ]. By contrast, other movement disorders typically begin gradually and without provocation, except when the underlying cause is an acute illness such as a stroke.
        </p>
        <p>
         Progression to maximum symptom severity and disability is often rapid, which is uncommon in other movement disorders. Illness, surgery, and physical injuries are common precipitants, including minor injuries (eg, lifting a moderate weight or following a nonconcussive motor vehicle accident). Often more than one type of movement disorder is present, which can be a helpful clue to the diagnosis.
        </p>
        <p>
         Once FMD is established, abnormal movements can be present constantly or occur as discrete episodes with periods of normal functioning. Patients very often describe "good days and bad days," with variation in their function accordingly. Pain, fatigue, and cognitive symptoms are often present at a constant low level or may be the dominant symptom in some patients. Disability and unemployment due to functional symptoms or other health concerns are common but not universal.
        </p>
        <p>
         Trials of medications and other therapeutic interventions for movement disorders have variable results in FMD, and symptoms may be much more or much less responsive than would be expected. Examples include complete remission of Parkinson-like symptoms with herbal remedies [
         <a href="#rid44">
          44
         </a>
         ] and immediate resolution of fixed dystonia with injections of botulinum toxin, even though the neuromuscular blocking effect of botulinum toxin requires at least 72 hours before a clinical impact can be observed [
         <a href="#rid45">
          45
         </a>
         ]. Lack of response to
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         for suspected Parkinson disease should be interpreted cautiously, as poor responses can also be characteristic of atypical parkinsonism.
        </p>
        <p class="headingAnchor" id="H3433697417">
         <span class="h2">
          Functional tremor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional tremor is the most common type of FMD. Tremor is defined as a rhythmic and oscillatory movement of a body part with a relatively constant frequency. (See
         <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">
          "Overview of tremor"
         </a>
         .)
        </p>
        <p>
         Functional tremor typically occurs with rest, posture, and action. Any body part may be involved, but hand tremor, leg tremor, and whole-body tremor are common sites [
         <a href="#rid46">
          46
         </a>
         ]. A feeling of "internal" tremor is common although not specific to FMD. In the upper limbs, the fingers are often spared, with much of the tremor occurring at the wrist [
         <a href="#rid18">
          18,47
         </a>
         ].
        </p>
        <p>
         There are numerous positive signs of functional tremor, including hallmark signs of distractibility, variability, and entrainability.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distractibility
         </strong>
         – Distractibility refers to complete remission or temporary suspension of the tremor with a cognitive or motor task. A common distraction maneuver is to ask the patient to hold the arms outstretched, and once the tremor is established, ask the patient to count through each of their fingers in order on the contralateral hand. Other potent distraction techniques include the history portion of the assessment and standard cranial nerve examination [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="local">
          'Distractibility'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Variability
         </strong>
         – Variability manifests as changes in tremor distribution, direction, frequency, and amplitude at different time points during the assessment, or over time on history. (See
         <a class="local">
          'Variability'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Entrainment
         </strong>
         – Entrainment refers to a shift of tremor frequency to match an externally or internally directed competing rhythmic movement with another body part. Some patients can "self-entrain" to stop their own functional tremor. Entrainment can also be demonstrated electrophysiologically in selected cases. (See
         <a class="local">
          'Electrodiagnostic testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Co-contraction
         </strong>
         – Patients with functional tremor may have isometric contraction of antagonist muscles in the tremoring body part  (
         <a class="graphic graphic_movie graphicRef139682" href="/z/d/graphic/139682.html" rel="external">
          movie 1
         </a>
         ). This ongoing co-contraction may be perceived on examination as increased muscle tone during passive movement [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          "Whack-a-mole" sign
         </strong>
         – Movement suppression of one body part (eg, holding an individual's wrist) may be followed by immediate re-emergence of movement in another body part [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to weight load
         </strong>
         – Functional tremor may increase in amplitude with weight load [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pause with ballistic movement
         </strong>
         – Tremor may temporarily arrest when the patient is asked to perform a ballistic movement of the contralateral arm  (
         <a class="graphic graphic_movie graphicRef139681" href="/z/d/graphic/139681.html" rel="external">
          movie 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Electrophysiologic studies may be helpful in distinguishing functional tremor in challenging cases with inconsistent or hard-to-elicit positive signs. (See
         <a class="local">
          'Electrodiagnostic testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2443021207">
         <span class="h2">
          Functional dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional dystonia is the second most common type of FMD. Dystonia refers to sustained or intermittent muscle contractions causing abnormal, often repetitive movements, postures, or both. Dystonic movements are typically patterned and twisting, and may be accompanied by tremor, which is usually slow and irregular. Dystonia is often initiated or worsened by voluntary action and associated with unintentional muscle contraction (overflow muscle activation). (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Functional dystonia is often described by the patient as "spasms" and may affect any part of the body (focal) or multiple areas at once (generalized). Clinical features and positive signs fall into three main phenotypes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fixed focal postures
         </strong>
         – Common focal presentations of functional dystonia include fixed plantarflexion/inversion of the ankles  (
         <a class="graphic graphic_figure graphicRef139678" href="/z/d/graphic/139678.html" rel="external">
          figure 1
         </a>
         ) and fixed finger flexion sparing the pincer grasp  (
         <a class="graphic graphic_figure graphicRef139679" href="/z/d/graphic/139679.html" rel="external">
          figure 2
         </a>
         ). Fixed postures are rare in nonfunctional dystonia. Patients typically display marked resistance to passive movement when the limb is at rest. Pain and sensory disturbances are often present, although not always. In severe cases, muscle atrophy or joint contractures may be present due to disuse or prolonged maintenance of the tonic posture.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most cases of dystonia after peripheral trauma are probably examples of functional focal dystonia [
         <a href="#rid8">
          8,53
         </a>
         ]. The entity may be termed peripherally induced dystonia, fixed dystonia, traumatic or posttraumatic dystonia, posttraumatic cervical dystonia, posttraumatic painful torticollis, causalgia-dystonia syndrome, and complex regional pain syndrome dystonia (formerly reflex sympathetic dystrophy dystonia) [
         <a href="#rid8">
          8,53-59
         </a>
         ]. In most cases, the precipitating trauma is minor. The inciting injury may involve nerve root, peripheral nerve, or soft tissue. Although the mechanism is controversial [
         <a href="#rid60">
          60-66
         </a>
         ], there is little evidence to support an organic basis, while the overlap with FMD features is extensive [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Positive signs include the presence of a fixed posture typical of functional dystonia, dramatic/immediate resolution with interventions (eg, physiotherapy, placebo, low-dose botulinum toxin injection), and lack of dynamic features such as overflow or a sensory trick. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dynamic and temporal features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional
         </strong>
         <strong>
          cranial dystonias
         </strong>
         – Functional facial spasms are a common subtype of functional dystonia. Concomitant jaw pain is common, and dental procedures are a trigger in some patients. Facial spasms may be solitary or occur in combination with episodic generalized dystonic spasms. Platysma overactivation is often present and may be misinterpreted as lower facial weakness, such as a facial droop seen in stroke. Functional facial dystonia is remarkably consistent between individuals with recognizable features [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A case series of 61 patients with facial FMD showed episodic or sustained muscular spasms resembling dystonia in all patients, most commonly involving the lips (61 percent), eyelids (51 percent), perinasal region (16 percent), and forehead (10 percent) [
         <a href="#rid67">
          67
         </a>
         ]. The most common pattern consisted of tonic, sustained, lateral, and/or downward protrusion of one side of the lower lip with ipsilateral jaw deviation  (
         <a class="graphic graphic_picture graphicRef134899" href="/z/d/graphic/134899.html" rel="external">
          picture 1
         </a>
         ). More than half of patients had ipsi- or contralateral tonic eye closure and excessive platysma contraction in isolation or combined with fixed lip dystonia. Spasms were reported as painful in 25 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Positive signs of functional facial spasms include downward lip-pulling, orbicularis oculi spasm, jaw deviation, and platysma overactivation. Signs that can help distinguish functional facial movements from those of tardive dyskinesia include lack of chewing movements or self-biting, lingual movements without mouth movements, and the presence of abnormal speech. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Oro-bucco-lingual and facial dyskinesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other common patterns include constant tonic eye closure, constant bilateral eye closure with the absence of prominent muscle activity (resembling ptosis), and contraction of corrugator and procerus muscles casing a narrowed palpebral fissure without involvement of orbicularis oculi.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal mixed dystonia
         </strong>
         – The most common form of generalized functional dystonia is paroxysmal mixed dystonia. These are nonstereotyped episodes, which often have mixed movements that do not conform to a single phenomenology (ie, elements of dystonia, ataxia, chorea, and ballism). Associated symptoms of pain or dissociative-like symptoms are common. Episodes may share overlapping features with nonepileptic seizures [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2591260277">
         <span class="h2">
          Functional gait
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional gait disorders can occur as an isolated FMD or in combination with other FMD phenotypes. Examples of mixed FMD include functional leg weakness causing a leg-dragging gait and functional fixed lower-limb dystonia causing a dystonic gait [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Numerous functional gait patterns have been described, including [
         <a href="#rid31">
          31,70-73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive slowness and stiffness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Knee-buckling gait
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leg-dragging gait
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dystonic gait
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Astasia-abasia, an inability to stand (astasia) or walk (abasia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Walking on ice"
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uneconomic gait
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bizarre gait (ie, not conforming to any of the usual patterns observed with neurologic gait disorders)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of postural control on a narrow base with flailing arms and excessive trunk sway
        </p>
        <p>
        </p>
        <p>
         Knowledge of gait patterns is essential in diagnosing functional gait disorders. The mere presence of a cautious gait does not confirm a functional etiology. A cautious gait may be a legitimate psychological adaptation, based upon an appropriate response to real or perceived disequilibrium [
         <a href="#rid74">
          74
         </a>
         ]. In addition to appropriate caution and fear of falling, the differential diagnosis of cautious gait includes higher-level frontal (apraxic) gait disorders. (See
         <a class="medical medical_review" href="/z/d/html/4910.html" rel="external">
          "Approach to abnormal gait in adults", section on 'Stiffness without weakness'
         </a>
         .)
        </p>
        <p>
         Bizarre gait patterns are also not always functional and may be seen in patients with dystonia syndromes. In these cases, the diagnostic clue of a functional etiology is variability, or the inconsistency of the bizarre functional gait. By contrast, dystonic gaits will be consistently "bizarre" (ie, the same gait pattern is consistently repeated and the same deficits present at the same point in the gait cycle) [
         <a href="#rid75">
          75
         </a>
         ]. An exception to this consistency occurs in patients with lower-limb dystonia, who may appear to have a foot drop when walking forward but not backward (when the dystonia consistently resolves).
        </p>
        <p>
         Positive signs for functional gait include dragging monoplegic gait, huffing and puffing, falling toward support, excessive slowness, hesitation, noneconomic posture, and knee-buckling [
         <a href="#rid76">
          76-78
         </a>
         ]. Asking a patient with gait disorder to propel themselves forwards and backwards in a rolling chair while sitting can aid in the assessment of improvement in functional gait; the adoption of a normal walking-like pattern while seated may be a positive sign [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2757079184">
         <span class="h2">
          Functional myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myoclonus is a brief, shock-like muscle contraction (positive myoclonus) or a sudden lapse in tone (negative myoclonus or asterixis) of the affected body part. Patients will usually describe myoclonus as consisting of "jerks," "shakes," or "spasms." Myoclonic movements have many possible etiologies and pathophysiologic features. (See
         <a class="medical medical_review" href="/z/d/html/4885.html" rel="external">
          "Classification and evaluation of myoclonus"
         </a>
         .)
        </p>
        <p>
         Functional myoclonus may be underrecognized in patients presenting with sudden body jerks, particularly when they involve the trunk or axial muscles. In one systematic review of 179 published cases identified as having propriospinal myoclonus, functional myoclonus was diagnosed in 57 percent [
         <a href="#rid81">
          81
         </a>
         ]. Characteristics that suggest functional myoclonus include [
         <a href="#rid82">
          82
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inconsistent character of the movements (amplitude, frequency, and/or distribution)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated functional symptomatology
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Marked reduction of the myoclonus with distraction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spontaneous periods of remission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute onset and sudden resolution
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of underlying psychopathology
        </p>
        <p>
        </p>
        <p>
         Positive signs for functional myoclonus/jerks, as with tremor, include variability and distractibility. The localization can help diagnostically, as functional jerks are often axial when other types of myoclonus occur in the limbs. Arrhythmic jerks of the trunk, hips, and knees, classically recognized as propriospinal myoclonus, can also be functional when positive signs are present (distractibility, variability) [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Distractibility'
         </a>
         below and
         <a class="local">
          'Variability'
         </a>
         below.)
        </p>
        <p>
         Electrodiagnostic testing can be helpful in differentiating functional myoclonus from other myoclonus. (See
         <a class="local">
          'Electrodiagnostic testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3320438408">
         <span class="h2">
          Functional parkinsonism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cardinal motor manifestations of parkinsonism are rest tremor, bradykinesia, rigidity, and postural instability (see
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease", section on 'Cardinal features'
         </a>
         ). Manifestations of functional parkinsonism can be superficially similar but have features suggesting a functional origin, including the presence of other functional signs and symptoms [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tremor
         </strong>
         – The tremor of functional parkinsonism shares the characteristics of isolated functional tremor (see
         <a class="local">
          'Functional tremor'
         </a>
         above), manifesting as a complex resting, postural, and action tremor with abrupt onset, a static course, and changeable features [
         <a href="#rid31">
          31,84-86
         </a>
         ]. Movements may include violent shaking of one arm or generalized violent shaking [
         <a href="#rid83">
          83
         </a>
         ]. The tremor will typically increase with attention and decrease with distraction [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bradykinesia
         </strong>
         – Functional bradykinetic movements are slow and effortful but lack the typical decrement in speed or amplitude that is observed with successive movements in true bradykinesia (ie, slowing without decrement).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rigidity
         </strong>
         – A functional increase in muscle tone is the result of gegenhalten/paratonia rather than true rigidity (ie, involuntary resistance to passive movement). Cogwheeling is absent. Of note, gegenhalten can also be seen in older adults, especially those with dementia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postural instability
         </strong>
         – Atypical gait abnormalities and postural instability are often present in functional parkinsonism. Postural stability testing may reveal positive signs such as arm-flailing and reeling backward without falling.
        </p>
        <p>
        </p>
        <p>
         In patients who have been exposed to
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         as a trial, lack of a response may be suggestive of functional parkinsonism (although atypical parkinsonian syndromes are also poorly responsive to levodopa). On the other hand, many patients with functional parkinsonism have complete symptom resolution with levodopa due to a placebo effect.
        </p>
        <p>
         Importantly, features of functional parkinsonism may coexist with Parkinson disease, and some evidence suggests that functional parkinsonism can be an early manifestation of Parkinson disease [
         <a href="#rid83">
          83,87,88
         </a>
         ]. Patients with functional parkinsonism should be followed longitudinally to examine for emerging Parkinson disease. A helpful distinguishing historical feature is that functional parkinsonism will not present with a prodrome suggestive of alpha-synuclein pathology (eg, constipation, depression, anosmia, or rapid eye movement [REM] sleep behavior disorder), as seen in most patients with Parkinson disease. A notable exception is tremor-dominant Parkinson disease, which may not display these features either, at least in the early stages. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease"
         </a>
         .)
        </p>
        <p>
         Knowledge of atypical parkinsonian disorders is also crucial in some cases to avoid misdiagnosis. As an example, a patient presenting with a very symmetric akinetic rigid syndrome without tremor may be erroneously diagnosed with functional parkinsonism. In fact, such a presentation is common among other parkinsonian syndromes such as multiple system atrophy and progressive supranuclear palsy. (See
         <a class="medical medical_review" href="/z/d/html/4890.html" rel="external">
          "Multiple system atrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14136.html" rel="external">
          "Progressive supranuclear palsy (PSP): Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14135.html" rel="external">
          "Corticobasal degeneration"
         </a>
         .)
        </p>
        <p>
         A normal dopamine transporter imaging study using single-photon emission computed tomography (SPECT) scan is helpful for supporting a diagnosis of either functional, drug-induced, or vascular parkinsonism, rather than nigrostriatal degeneration [
         <a href="#rid89">
          89
         </a>
         ]. However, scans can change from normal to abnormal over time, and, therefore, a single test should not be used to support a diagnosis of FMD. (See
         <a class="local">
          'Neuroimaging'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'DaTscan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H222109302">
         <span class="h2">
          Functional tics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tics are recurrent, semivoluntary, stereotyped movements that can be either vocal or motor, simple or complex. There is a narrow repertoire of tics in an individual, which may change over time. Tics are accompanied by a premonitory urge to perform the movement, discomfort if the tic is contained, and relief after the tic is performed. Tics are common in children, with a prevalence of 6 to 12 percent. (See
         <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">
          "Hyperkinetic movement disorders in children", section on 'Tic disorders'
         </a>
         .)
        </p>
        <p>
         Functional tics are challenging to diagnose, largely because nonfunctional tics have many of the same clinical characteristics. Many of the shared features that help differentiate FMD from other movement disorders (eg, sudden onset, distractibility, suggestibility, temporary remissions, and a fluctuating course) are also common clinical features of nonfunctional tics [
         <a href="#rid90">
          90
         </a>
         ]. This may be why functional tics are rarely reported, accounting for only 2 percent of FMD [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         An increase in functional tics has been observed during the coronavirus disease 2019 (COVID-19) pandemic [
         <a href="#rid92">
          92-94
         </a>
         ]. Cases have been referred to as "TikTok tics," as affected individuals have commonly viewed online videos depicting tic-like behaviors. Most patients are females between 15 and 25 years of age [
         <a href="#rid92">
          92
         </a>
         ]. Symptom onset is usually acute, with complex vocal and motor tics involving large-amplitude arm movements, self-injury, and a wide range of odd words or phrases, often with obscenities (coprolalia). Comorbid anxiety and depression are common.
        </p>
        <p>
         Positive signs for functional tics include an inability to voluntarily suppress the movement, incomplete premonitory urge, and lack of fully stereotyped movements [
         <a href="#rid90">
          90
         </a>
         ]. Coprolalia, particularly complex phrases, more commonly occurs in functional tics and is relatively rare in nonfunctional tics. In general, it is not common for tics to begin de novo in adults, and the presence of this alone should raise suspicion for a functional tic disorder.
        </p>
        <p class="headingAnchor" id="H4057337212">
         <span class="h1">
          COMORBIDITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a functional neurological symptom disorder, FMD is highly comorbid with psychiatric, neurologic, and medical illnesses. Comorbidities are important to recognize as they may contribute to symptom genesis, perpetuation, and treatment response.
        </p>
        <p>
         Patients have high rates of depression, generalized anxiety, panic, posttraumatic stress, and dissociative and somatoform symptom disorders. Personality disorders are also more common than in patients with neurologic disease, especially borderline, histrionic, and narcissistic types. (See
         <a class="medical medical_review" href="/z/d/html/85765.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Clinical features, assessment, and comorbidity", section on 'Psychiatric disorders'
         </a>
         .)
        </p>
        <p>
         Chronic pain, fatigue, anxiety, and cognitive symptoms are common in patients with FMD and occur at higher rates than formal psychiatric diagnoses [
         <a href="#rid15">
          15,95
         </a>
         ]. Anxiety is especially common in patients with functional tremor but may not present overtly. Coexisting nonmotor functional symptoms, including functional seizures, sensory symptoms, visual symptoms, bladder changes, and irritable bowel symptoms, are also common. Comorbid movement disorders are diagnosed in approximately 15 to 25 percent of patients with FMD [
         <a href="#rid9">
          9,96
         </a>
         ].
        </p>
        <p>
         Some patients report prior suicidal ideation or suicide attempts [
         <a href="#rid38">
          38,72
         </a>
         ], self-injurious behaviors [
         <a href="#rid97">
          97
         </a>
         ], and psychiatric hospitalizations [
         <a href="#rid38">
          38
         </a>
         ]. Increased harm avoidance and impulsivity, decreased novelty-seeking, self-directedness and active problem-solving, and external rather than internal locus of control have all been described in FMD [
         <a href="#rid60">
          60-62
         </a>
         ]. Alexithymia, or difficulty recognizing emotion, has also been associated with FMD [
         <a href="#rid38">
          38
         </a>
         ], but this remains controversial.
        </p>
        <p class="headingAnchor" id="H590744064">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FMD is diagnosed clinically based upon characteristic clinical features and demonstration of positive signs  (
         <a class="graphic graphic_table graphicRef134880" href="/z/d/graphic/134880.html" rel="external">
          table 4
         </a>
         ). FMD should be suspected in patients with movements or postures that do not conform to usual characteristics of neurologic disorders; although psychiatric comorbidity is common, it is not always evident at the time of presentation and is not required for the diagnosis.
        </p>
        <p>
         The diagnosis of FMD is best made by clinicians with expertise in movement disorders, including general neurologists [
         <a href="#rid98">
          98
         </a>
         ]. An accurate diagnosis depends not only on the ability to recognize the characteristic features of FMD, but also on a strong knowledge of other movement disorders and their common and rare variants.
        </p>
        <p class="headingAnchor" id="H907728359">
         <span class="h2">
          General principles
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rule-in, not rule-out
         </strong>
         – FMD is a "rule-in" diagnosis that requires the presence of characteristic clinical features  (
         <a class="graphic graphic_table graphicRef50039" href="/z/d/graphic/50039.html" rel="external">
          table 3
         </a>
         ) and the demonstration of positive signs  (
         <a class="graphic graphic_table graphicRef134880" href="/z/d/graphic/134880.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid99">
          99,100
         </a>
         ]. FMD is not a diagnosis of exclusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidity
         </strong>
         – Coexisting psychological factors and psychiatric disorders are not required for a diagnosis of FMD [
         <a href="#rid4">
          4
         </a>
         ]. Pain, fatigue, and cognitive symptoms are common. FMD can coexist with other neurologic illness, including other movement disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of investigations
         </strong>
         – Investigations should be done as appropriate to rule out comorbid neurologic disease. Laboratory-supported diagnoses with electrophysiology can be used in challenging cases of functional tremor or myoclonus. (See
         <a class="local">
          'Electrodiagnostic testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rate of
         </strong>
         <strong>
          misdiagnosis
         </strong>
         –
         <strong>
         </strong>
         Misdiagnosis is rare in patients who receive an appropriate neurologic evaluation. A systematic review found that the misdiagnosis rate for patients with various functional symptoms, including some with abnormal movements, has been 4 percent since the 1970s [
         <a href="#rid101">
          101
         </a>
         ]. While not specific for FMD, this finding suggests that the misdiagnosis rate is not unacceptably high compared with other psychiatric and neurologic disorders [
         <a href="#rid102">
          102
         </a>
         ]. In some cases, FMD may be the presenting syndrome heralding development of another neurologic disease, and patients should be reevaluated in the setting of new or changing symptoms [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2012251186">
         <span class="h2">
          Diagnostic criteria (DSM-5)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classifies abnormal functional movements as a subtype of functional neurological symptom disorder (conversion disorder) [
         <a href="#rid1">
          1
         </a>
         ]. A DSM-5 diagnosis of conversion disorder requires symptoms of altered voluntary motor or sensory function, incompatibility with a recognized neurologic or general medical condition, lack of a better explanation, and the presence of significant distress or psychosocial impairment  (
         <a class="graphic graphic_table graphicRef91102" href="/z/d/graphic/91102.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14826.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Terminology, diagnosis, and differential diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2773654341">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         History and direct observation are the core components of the diagnostic evaluation. Clinicians should ask about all of the following items, each of which is discussed in more detail separately (see
         <a class="medical medical_review" href="/z/d/html/85765.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Clinical features, assessment, and comorbidity", section on 'History'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All current symptoms (neurologic, constitutional, psychological)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Circumstances at onset of symptoms (injury, illness, procedures)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Course of illness (duration, variability, triggers, alleviating factors, treatment trials, remissions)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disability (physical, psychosocial, occupational)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ideas, concerns, and expectations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychosocial functioning
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dissociation (feeling disconnected from oneself or the environment)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history (neurologic disorders, psychiatric disease, functional disorders)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous functional symptoms and disorders
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior clinical experiences (misdiagnosis, iatrogenesis, excess tests and medication trials; often major source of mistrust and powerlessness)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent psychological stressors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of comorbid psychiatric disorders
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2718296387">
         <span class="h2">
          Examination and positive signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Positive signs  (
         <a class="graphic graphic_table graphicRef134880" href="/z/d/graphic/134880.html" rel="external">
          table 4
         </a>
         ) are essential in diagnosing FMD [
         <a href="#rid1">
          1
         </a>
         ]. Among functional neurological symptom disorders, movement disorders are particularly amenable to positive signs on examination that aid the clinician to rule in a correct diagnosis. Demonstrating the positive sign to the patient is also an invaluable means of explaining the diagnosis, and it is useful when suggesting treatment approaches (See
         <a class="local">
          'Education'
         </a>
         below.)
        </p>
        <p>
         The hallmark positive signs in FMD are internal inconsistency and incongruence with known patterns of abnormal movement seen in other neurologic diseases. Internal inconsistency refers to the tendency of the symptom to change over time or depending on the context and includes variability, distractibility, and augmentation with attention. These features apply to almost all FMD phenotypes. Additional positive signs specific to certain phenotypes are described above (see
         <a class="local">
          'Clinical features'
         </a>
         above) and listed in the table  (
         <a class="graphic graphic_table graphicRef134880" href="/z/d/graphic/134880.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Positive signs have shown a wide range of sensitivity (9 to 100 percent) but tighter range of specificity (64 to 100 percent) in functional motor and sensory symptom disorders, with 37 out of 41 signs having a specificity over 90 percent [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1460155367">
         <span class="h3">
          Distractibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distracting maneuvers temporarily diminish the intensity of FMD or suppress it entirely. By contrast, distracting maneuvers usually increase the intensity of abnormal movements in other movement disorders (such as dyskinesia in Parkinson disease).
        </p>
        <p>
         Distraction techniques can be cognitive or motor and must be of sufficient difficulty to truly distract the patient.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive distractions
         </strong>
         – Examples include the history portion of the assessment, reciting the months of the year backward, listing animals, and generating
         <strong>
         </strong>
         words that begin with the same letter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Motor distractions
         </strong>
         – Examples include the cranial nerve examination (ocular and oral movements are potent distractions if the functional movements do not involve the face), finger-counting in the contralateral hand, and asking the patient to draw letters or numbers in the air with their upper limb or on the floor with their foot. The distracting motor task must also be used in a part of the body not involved in the abnormal movement  (
         <a class="graphic graphic_movie graphicRef139681" href="/z/d/graphic/139681.html" rel="external">
          movie 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Distracting maneuvers may not be effective in longstanding FMD [
         <a href="#rid104">
          104
         </a>
         ]. Fixed dystonia, functional myoclonus, and episodic or paroxysmal FMD are also less amenable to distraction. A corollary positive sign to distraction is when the symptom enhances when attention is drawn to it, either when the patient is describing it during the history, when it is pointed out by the examiner, or when the patient is engaging in a voluntary task that involves the body part with the symptom of concern (eg, writing in a patient with a functional dominant-hand tremor).
        </p>
        <p class="headingAnchor" id="H1487823799">
         <span class="h3">
          Variability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Variability is a core feature of FMD. Functional symptoms wax and wane over time. Variability can refer to the natural history of a symptom over time (by history) or at different points during the assessment. Functional movements may vary in terms of frequency, amplitude, direction, or location in the body.
        </p>
        <p>
         Variation with body position is common in FMD. Seated findings may not correlate with the same findings while the patient is lying supine or walking. Findings may be different in the waiting room versus the clinic room.
        </p>
        <p class="headingAnchor" id="H598684671">
         <span class="h2">
          Electrodiagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrodiagnostic methods can provide additional supportive evidence for the diagnosis of functional tremor and functional myoclonus. However, electrodiagnostic methods for analyzing tremor and myoclonus require special expertise, are not universally available, and depend on patient effort for accuracy. They are not required or indicated in the majority of patients.
        </p>
        <p>
         There are no definitive electrodiagnostic tests for distinguishing functional dystonia from other forms of dystonia [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tremor analysis
         </strong>
         – Tremor analysis using surface electromyography (EMG) and accelerometry can identify features associated with functional tremor, including entrainment, coactivation of antagonist muscles, variability in tremor frequency, and increased tremor amplitude and frequency with weight-loading of the involved limb [
         <a href="#rid25">
          25,47,104,106-108
         </a>
         ]. Coherence analysis is a quantitative method to determine the similarity of tremor oscillation frequency and phase in different limbs or body parts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Functional tremor typically has the same frequency in different limbs, and changes in frequency are simultaneous when they occur [
         <a href="#rid109">
          109
         </a>
         ]. By contrast, most other forms of tremor, including essential tremor and parkinsonian tremor, have similar but slightly different frequencies in different body parts, consistent with the presence of multiple oscillators [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Entrainment is a property whereby a functional tremor synchronizes with the frequency of voluntary tapping of another body part, most often the opposite hand. The degree of similarity of tremor frequency with voluntary tapping can be assessed by coherence analysis. Lack of entrainment suggests another etiology of tremor, since essential tremor and parkinsonian tremor maintain their original frequencies and do not entrain. However, in some cases functional tremor will stop or change frequency rather than show clear entrainment. [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myoclonus analysis
         </strong>
         – Electrodiagnostic techniques, including surface EMG, electroencephalography (EEG), back-averaged EEG, and somatosensory evoked potentials, can be helpful in differentiating functional myoclonus from true myoclonus. Features associated with functional myoclonus on surface EMG include abnormally long and variable latency between the stimulus and the myoclonic jerk, variable patterns of muscle recruitment with each jerk, prolonged myoclonic burst duration, a triphasic pattern of agonist and antagonist muscle activation, and habituation with repeated stimulation [
         <a href="#rid110">
          110,111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In organic myoclonus of cortical origin, the myoclonic jerk has a short latency of 60 to 70 ms after a stimulus-induced cortical evoked potential on EEG and consists of short-duration (10 to 50 ms) burst activity in an agonist muscle on EMG accompanied by co-contraction in antagonist muscles. Brainstem myoclonus has short latencies (less than 80 ms) affecting the upper body. A pattern consistent with voluntary movement (ie, a long latency of 100 to 120 ms from stimulus to jerk) is suggestive of functional myoclonus. In addition, functional myoclonus is usually but not always preceded by a Bereitschaftspotential, which is a normal movement-related cognitive potential indicative of premotor activity that occurs prior to movement on back-averaged EEG [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4030580846">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuroimaging is usually obtained to exclude the possibility of a coexisting structural abnormality alongside FMD, such as demyelination or a compressive radiculopathy. The decision to image and the specific study should be based on clinical suspicion. Brain magnetic resonance imaging (MRI) is often the appropriate study, although a spine MRI may also be indicated for certain cases of myoclonus, dystonia, or tremor when symptoms involve a single limb. Care must be taken in explaining to patients why investigations are being done and to prepare the patient for potentially incidental findings.
        </p>
        <p>
         Striatal dopamine transporter imaging using 123I-FP-CIT single-photon emission computed tomography (DaTscan) is not routinely indicated in the evaluation of FMD and is not specific for a functional cause. In a patient with parkinsonism, a normal DaTscan would be supportive of several diagnoses, including functional, drug-induced, or vascular parkinsonism [
         <a href="#rid89">
          89
         </a>
         ]. In addition, a change from normal to abnormal may occur over time, and, therefore, a single test should not be used to support a diagnosis of FMD. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease", section on 'DaTscan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1730258805">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         An accurate diagnosis of FMD depends on strong knowledge of other movement disorders and their common and rare variants. Movement disorders that may be confused with functional movements vary based on the particular movement and are discussed above. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         The differential diagnosis of functional neurological symptom disorder can also include psychiatric disorders, including somatic symptom disorder, depersonalization/derealization disorder, feigned symptoms, factious disorder, and malingering. The distinction between these disorders and functional disorders is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14826.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Terminology, diagnosis, and differential diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1018433967">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of FMD follows the same principles of therapy as for functional neurological symptom disorder. Treatment should be individualized and follow a stepped model of care based on symptom severity and complexity to optimize resource allocation [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Step 1
         </strong>
         – All patients should be provided with a diagnosis, education, and advice by a neurologist as first-line therapy. (See
         <a class="local">
          'Delivering the diagnosis'
         </a>
         below and
         <a class="local">
          'Education'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Step 2
         </strong>
         – Patients with more severe symptoms but without complex psychiatric comorbidities may benefit from a brief rehabilitation intervention with a physical, occupational, or speech therapist, with or without accompanying psychotherapy. (See
         <a class="local">
          'Motor retraining'
         </a>
         below and
         <a class="local">
          'Psychological therapies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Step 3
         </strong>
         – Patients with complex symptom presentations, those with a high level of disability and comorbidities, and those who have failed prior treatment interventions may require specialized multidisciplinary therapy delivered in an outpatient, day hospital, or inpatient setting [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="local">
          'Multidisciplinary therapies'
         </a>
         below and
         <a class="local">
          'Refractory/chronic disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3636813628">
         <span class="h2">
          Delivering the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first line of treatment consists of disclosing the diagnosis to the patient. Clinicians should demonstrate the rationale for the diagnosis of FMD, show the patient their positive signs, and convey recovery potential.
        </p>
        <p>
         It should be emphasized that the problem is not "made up" by the patient, or "in their head," or "put on." FMD is a real and common condition. It is important to take the patient's complaints seriously. Some patients with FMD will have had prior negative experiences with health care providers, and inquiring about these instances while also validating the patient's symptom complex can help build rapport and engagement [
         <a href="#rid12">
          12
         </a>
         ]. Importantly, some patients will improve with a well-delivered diagnosis alone.
        </p>
        <p>
         A roadmap for presenting the diagnosis is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Presenting the diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H916527657">
         <span class="h2">
          Education
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be directed to reliable sources of information about FMD. Some neurologists find it useful to review symptoms with the patient using a website,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.neurosymptoms.org%2Fen_US%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8R5PPOnfP%2F4w2jB5ti5fdkJn%2Fc4%2BGTp1MyoC6HEUJe7&amp;TOPIC_ID=14132" target="_blank">
          FND Guide
         </a>
         , which presents balanced information about functional neurological symptom disorders including FMD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Demonstration
         </strong>
         – Showing the patient their positive signs is a valuable way to help the patient agree with and understand the diagnosis, particularly in movement disorders [
         <a href="#rid115">
          115
         </a>
         ]. For example, demonstrating to the patient that their tremor temporarily resolves when they tap the fingers of their other hand shows them not only that distraction improves the tremor, but also that their nervous system is capable of functioning normally at times.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Entrainment
         </strong>
         – Entrainment can be used as a therapeutic strategy at the time of diagnosis at the bedside to show the patient that they can retrain the tremor frequency and reduce the tremor severity (ie, "self-entrain") [
         <a href="#rid116">
          116
         </a>
         ]. This tends to be most useful for unilateral functional hand tremor. The contralateral hand taps the leg at a fast frequency that matches the frequency of the tremor. The patient then deliberately slows down the frequency until it stops, and the entrained hand also stops.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of analogies
         </strong>
         – Explaining the diagnosis can be made easier through the use of analogies, such as a "hardware versus software" problem, or abnormal motor programs learned by the brain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3517629235">
         <span class="h2">
          Role of psychiatry referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of the psychiatrist ranges from diagnostic elaboration to the provision of treatment. The reason why psychiatric referral would be helpful should be clearly communicated to the patient (ie, to help us understand your brain better, not for diagnostic confirmation) so they can make an informed decision if they wish to have an evaluation.
        </p>
        <p>
         Involving psychiatry is vital at the time of diagnosis when comorbid psychiatric diagnoses are suspected and/or previously identified and not optimized, such as untreated anxiety or depression, posttraumatic stress, personality traits, dissociation, or unusual symptoms such as psychosis. Alternatively, psychiatric evaluation can identify relevant risk factors (such as trauma) and psychosocial perpetuating factors relevant to treatment triage. In these cases, developing a partnership between neurology and psychiatry and using a similar framework of understanding goes a long way in reducing stigma, countering dualism, and building a positive therapeutic relationship.
        </p>
        <p class="headingAnchor" id="H3325914075">
         <span class="h2">
          Specialized therapies
         </span>
        </p>
        <p class="headingAnchor" id="H3710822511">
         <span class="h3">
          Motor retraining
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients who do not improve with education alone, we suggest specialized rehabilitation, which can be delivered by physiotherapists [
         <a href="#rid117">
          117
         </a>
         ], occupational therapists [
         <a href="#rid118">
          118
         </a>
         ], or speech therapists [
         <a href="#rid119">
          119
         </a>
         ],
         <strong>
         </strong>
         depending on the movement disorder. It is important to note that the principles of rehabilitation for FMD differ from traditional neurorehabilitation, so in ideal cases the therapist is familiar with FMD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eligibility and barriers
         </strong>
         – Prior to embarking on therapy, it is important to determine if any barriers to rehabilitation are present, such as severe pain or fatigue, diagnostic disagreement or alternate illness beliefs, or ongoing psychosocial stressors that will limit engagement [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is also important that the symptoms of concern to the patient (and not just the provider) are amenable to physiotherapy. For example, gait disorders or tremor that are present more or less constantly are more amenable to rehabilitation than episodic generalized dystonia, in which the symptoms are only intermittently present, or fixed dystonia, in which there is little to no variability present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic principles
         </strong>
         – The principles of motor-retraining physiotherapy differ markedly from standard neurorehabilitation; thus, working with a therapist with experience in these techniques is essential. Therapy is delivered within a psychologically informed framework, and relaxation and mindfulness training are incorporated into treatment sessions. FMD-specific therapy principles include [
         <a href="#rid117">
          117-120
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Address function, such as transfers and walking, rather than impairments such as weakness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Divert attention away from abnormal movements
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Notice symptom variability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use energy/activity rationing, also called pacing
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limit "hands-on" treatment
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Facilitate rather than support movements
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Encourage early weight-bearing
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use a goal-directed approach focused on function and automatic movement
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Minimize reinforcement of maladaptive movement patterns and postures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid adaptive equipment and mobility aids
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – There is now a good evidence base for physiotherapy for FMD, including several small, randomized trials [
         <a href="#rid117">
          117,121-123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A randomized trial compared three weeks of inpatient physical therapy (including education) with a waiting list control condition in hospitalized patients with psychogenic gait disorder (n = 60) [
         <a href="#rid122">
          122
         </a>
         ]. Ambulation and functional independence improved significantly more with physical therapy, the clinical effect was large, and the benefits were maintained at one-year follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A second randomized trial compared a five-day intensive outpatient specialized physical therapy program with standard neurologic physical therapy in 60 patients with functional motor disorders [
         <a href="#rid124">
          124
         </a>
         ]. The control group received an average of five sessions. At six-month follow-up, improvement occurred in four times as many patients in the intervention group than the controls (72 versus 18 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1290943135">
         <span class="h3">
          Psychological therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychiatric interventions are individualized according to the underlying psychiatric diagnosis and best accomplished by involvement with a psychiatrist or psychologist who is familiar with FMD.
        </p>
        <p>
         Patients may decline psychotherapy because they refuse to accept that "talking" treatments can be beneficial for physical symptoms. This concern can often be addressed by delivering psychotherapy as part of medical care, validating the patient's experience and symptoms as not being "all in their head," and using integrated care models with partnerships between neurology and psychiatry [
         <a href="#rid125">
          125,126
         </a>
         ]. In some cases, pharmacotherapy may be useful for comorbid, active psychiatric concerns such as depression or anxiety [
         <a href="#rid127">
          127
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Comorbid anxiety/depression/chronic pain'
         </a>
         .)
        </p>
        <p>
         In FMD, psychotherapy can be effective either in conjunction with motor retraining or delivered sequentially [
         <a href="#rid128">
          128-131
         </a>
         ]. As an example, functional tremor with accompanying anxiety can be treated with motor retraining physio- or occupational therapy to target tremor, in concert with cognitive-behavioral therapy (CBT) to target unhelpful thought patterns and anxiety. One study in 15 patients with functional tremor showed complete remission at 12 weeks in 73 percent of the cohort following a course of CBT alone [
         <a href="#rid131">
          131
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Cognitive-behavioral therapy'
         </a>
         .)
        </p>
        <p>
         Psychodynamic psychotherapy has a good evidence base in functional neurological symptom disorder. Studies in FMD are more limited, but there may be a role for individual psychotherapy with or without pharmacotherapy [
         <a href="#rid132">
          132
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Psychodynamic psychotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2986190258">
         <span class="h3">
          Multidisciplinary therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with complex symptom presentations, those with a high level of disability and comorbidities, and those who have failed prior treatment interventions may benefit from specialized multidisciplinary therapy delivered in an outpatient, day hospital, or inpatient setting.
        </p>
        <p>
         Inpatient programs for severe FMD cases have shown good clinical outcomes in observational studies [
         <a href="#rid8">
          8,133-137
         </a>
         ]. As an example, a prospective observational study assessed patients (n = 66) who were hospitalized on a specialist unit for severe conversion disorder (mixed subtype) and received a four-week multidisciplinary program that included physical therapy, occupational therapy, CBT, neuropsychiatry assessment, and neurology input as required. Improvement of psychiatric symptoms, behavior, and functioning at discharge was significant and clinically large, according to clinician ratings [
         <a href="#rid137">
          137
         </a>
         ]. General health was rated as "better" or "much better" by 66 percent of patients, both at discharge and the one-year follow-up assessment.
        </p>
        <p>
         Complex patients are more resource intensive and require specialized outpatient care as well. Such patients may benefit from dedicated functional neurological symptom disorder clinics where access to adjunctive treatments is available [
         <a href="#rid95">
          95
         </a>
         ], such as chronic pain programs, long-term psychotherapy, trauma therapy, and other therapies for non-movement-related functional symptoms such as vestibular therapy.
        </p>
        <p>
         Other therapies have been investigated in FMD and include transcranial magnetic stimulation [
         <a href="#rid138">
          138
         </a>
         ] and hypnosis [
         <a href="#rid128">
          128,139
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Third-line treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H983811315">
         <span class="h2">
          Refractory/chronic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A large proportion of patients will not respond to treatment and develop chronic FMD. It is important for the clinician to realize that the absence of a structural lesion does not mean that the problem will resolve on its own. Therapy for FMD is considered "opt-in," and many patients will not be ready to engage in treatment at a particular time. Applying treatment to a patient who is not ready to engage will generally be unsuccessful.
        </p>
        <p>
         Chronic FMD occurs for several possible reasons, including internal and external factors related to the patient and the health care team. Misdiagnosis and unrecognized comorbidities should always be considered when patients fail to respond to standard therapies. (See
         <a class="medical medical_review" href="/z/d/html/85766.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Treatment", section on 'Persistently ill patients'
         </a>
         .)
        </p>
        <p>
         In patients with chronic FMD, treatment may consist of periodic reassessments to ascertain readiness to engage in treatment, reassurance around new symptoms, and prevention of iatrogenic harm from diagnostic tests or surgical procedures. Persistently ill patients should generally be treated by primary care clinicians with a conservative approach, along the lines of prophylactic management models used in somatization disorder. (See
         <a class="medical medical_review" href="/z/d/html/110022.html" rel="external">
          "Somatic symptom disorder: Treatment", section on 'Treatment-refractory patients'
         </a>
         .)
        </p>
        <p>
         Identifying who may or may not respond to therapy upfront and triaging to appropriate treatments are important for resource allocation, given the prevalence of these disorders and the high health care utilization of this portion of the population.
        </p>
        <p class="headingAnchor" id="H2350208118">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognosis for functional neurological symptom disorder as a whole is guarded, and many patients face long-term symptoms and disability. Across subtypes, patients with sensory symptoms tend to do better than those with weakness/paralysis and FMD. (See
         <a class="medical medical_review" href="/z/d/html/85764.html" rel="external">
          "Functional neurological symptom disorder (conversion disorder) in adults: Epidemiology, pathogenesis, and prognosis", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         In a systematic review of FMD that identified 24 studies in 2069 patients, 40 percent of patients had the same or worse outcome with a median follow-up of 7.4 years, and only 20 percent of patients experienced complete remission [
         <a href="#rid140">
          140
         </a>
         ]. Among phenotypes, functional dystonia had the worst prognosis, with nearly 80 percent of patients having the same or worse symptoms over time [
         <a href="#rid140">
          140,141
         </a>
         ]. Functional tremor also has a relatively poor prognosis, with 44 to 90 percent of patients the same or worse at follow-up [
         <a href="#rid19">
          19,47,142,143
         </a>
         ]. An important limitation is that most prognostic studies have been in untreated cohorts.
        </p>
        <p>
         Baseline predictors of outcome in patients with FMD are similar to those in patients with other subtypes of functional neurological symptom disorder  (
         <a class="graphic graphic_table graphicRef138865" href="/z/d/graphic/138865.html" rel="external">
          table 5
         </a>
         ). There is conflicting evidence regarding the correlation of prognosis with pending litigation, age, comorbid anxiety and depression, intelligence quotient, educational status, and marital status [
         <a href="#rid140">
          140
         </a>
         ]. The interpretation of most prognostic studies is hampered because patients with functional symptoms were not compared with controls with recognizable neurologic disease.
        </p>
        <p>
         FMD often occurs in midlife, and the socioeconomic impact is notable. Patients with FMD show comparable rates of disability to those seen in other neurologic diseases, though with increased rates of total symptom burden and mental distress [
         <a href="#rid144">
          144,145
         </a>
         ].
         <strong>
         </strong>
         Unemployment rates range from 23 to 84 percent, and the reported percentage of patients who are receiving or seeking medical disability has ranged from 24 to 55 percent [
         <a href="#rid12">
          12
         </a>
         ].
         <strong>
         </strong>
         One multicenter study of FMD from Canada, the United Kingdom, and Switzerland found that 35 percent of patients were not working because of ill health, 26 percent were receiving disability benefits, and 10 to 38 percent required a care provider for daily activities [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1842656721">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Functional movement disorder (FMD) is a subtype of functional neurological symptom disorder (also known as conversion disorder)
         <strong>
         </strong>
         defined by abnormal movements that occur as a result of abnormal functioning of the nervous system, incongruent with known movement disorders. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – FMD accounts for 2 to 10 percent of all movement disorders. Functional tremor is the most frequent phenotype of FMD, followed by functional dystonia. Mixed FMD with more than one phenotype is common. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – FMD is best conceptualized using a biopsychosocial model of predisposing, precipitating, and perpetuating factors. Factors can be biologic, psychological, or social, and the combination of factors is unique to each patient  (
         <a class="graphic graphic_table graphicRef88079" href="/z/d/graphic/88079.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Etiologic factors'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – FMD often begins abruptly after illness or injury, has a fast progression to disability, and is associated with variable symptoms that wax and wane over time  (
         <a class="graphic graphic_table graphicRef50039" href="/z/d/graphic/50039.html" rel="external">
          table 3
         </a>
         ). Symptoms usually improve with distraction and worsen with attention. (See
         <a class="local">
          'Shared features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The main FMD syndromes are functional tremor, functional dystonia, functional gait, functional myoclonus, and functional parkinsonism. Each is associated with distinctive clinical features and positive signs that help distinguish FMD from other movement disorders  (
         <a class="graphic graphic_table graphicRef134880" href="/z/d/graphic/134880.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Functional tremor'
         </a>
         above and
         <a class="local">
          'Functional dystonia'
         </a>
         above and
         <a class="local">
          'Functional gait'
         </a>
         above and
         <a class="local">
          'Functional myoclonus'
         </a>
         above and
         <a class="local">
          'Functional parkinsonism'
         </a>
         above and
         <a class="local">
          'Functional tics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – FMD is a rule-in diagnosis and not a diagnosis of exclusion, and follow-up is required as clinically indicated. Accurate diagnosis is based on the entire clinical picture and demonstration of positive signs on examination. Coexisting psychological factors and psychiatric disorders are common but not required. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Laboratory-supported diagnosis can be achieved in challenging cases of tremor or myoclonus using electrodiagnostic studies, such as electromyography (EMG) and electroencephalography (EEG). Neuroimaging has a role when there is clinical suspicion for a coexisting structural abnormality alongside FMD. (See
         <a class="local">
          'Electrodiagnostic testing'
         </a>
         above and
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Optimal management of FMD consists of early diagnosis and individualized treatment depending on symptom severity and syndrome complexity. There is no "one size fits all" treatment. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment begins with diagnosis delivery. Clinicians should emphasize the rationale for the diagnosis, demonstrate to the patient their positive signs, convey the potential for reversibility, and provide educational resources, such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.neurosymptoms.org%2Fen_US%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8R5PPOnfP%2F4w2jB5ti5fdkJn%2Fc4%2BGTp1MyoC6HEUJe7&amp;TOPIC_ID=14132" target="_blank">
          FND Guide
         </a>
         . (See
         <a class="local">
          'Delivering the diagnosis'
         </a>
         above and
         <a class="local">
          'Education'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who do not improve with diagnosis and education alone are offered motor retraining physiotherapy, occupational therapy, or speech therapy. (See
         <a class="local">
          'Motor retraining'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychological therapies such as cognitive behavioral therapy can be effective adjuncts to physical therapy, either together or in sequence. (See
         <a class="local">
          'Psychological therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multidisciplinary rehabilitation in either in- or outpatient models may be required for more complex, longstanding, and/or highly disabled patients. (See
         <a class="local">
          'Multidisciplinary therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some patients will not improve with therapy. Management of chronic FMD should center around minimization of iatrogenic harm. (See
         <a class="local">
          'Refractory/chronic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Prognosis for FMD is generally unfavorable in untreated cohorts. Factors associated with a more favorable prognosis include short duration of symptoms, early diagnosis, and good therapeutic alliance with the clinician  (
         <a class="graphic graphic_table graphicRef138865" href="/z/d/graphic/138865.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H498401514">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Janis M Miyasaki, MD, MEd, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, American Psychiatric Association, Arlington 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone J, Campbell K, Sharma N, et al. What should we call pseudoseizures? The patient's perspective. Seizure 2003; 12:568.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. International Classification of Diseases, 11th Revision (ICD-11). https://www.who.int/classifications/classification-of-diseases (Accessed on October 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams DT, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 1995; 65:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J Neurol Neurosurg Psychiatry 1995; 59:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwingenschuh P, Pont-Sunyer C, Surtees R, et al. Psychogenic movement disorders in children: a report of 15 cases and a review of the literature. Mov Disord 2008; 23:1882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JE. Clinical Characteristics of Functional Movement Disorders: A Clinic-based Study. Tremor Other Hyperkinet Mov (N Y) 2018; 8:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 2004; 127:2360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirsch DB, Mink JW. Psychogenic movement disorders in children. Pediatr Neurol 2004; 30:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chouksey A, Pandey S. Functional Movement Disorders in Elderly. Tremor Other Hyperkinet Mov (N Y) 2019; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batla A, Stamelou M, Edwards MJ, et al. Functional movement disorders are not uncommon in the elderly. Mov Disord 2013; 28:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez DL, Aybek S, Popkirov S, et al. A Review and Expert Opinion on the Neuropsychiatric Assessment of Motor Functional Neurological Disorders. J Neuropsychiatry Clin Neurosci 2021; 33:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ani C, Reading R, Lynn R, et al. Incidence and 12-month outcome of non-transient childhood conversion disorder in the U.K. and Ireland. Br J Psychiatry 2013; 202:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephen CD, Fung V, Lungu CI, Espay AJ. Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders. JAMA Neurol 2021; 78:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinazzi M, Morgante F, Marcuzzo E, et al. Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Mov Disord Clin Pract 2020; 7:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cubo E, Hinson VK, Goetz CG, et al. Transcultural comparison of psychogenic movement disorders. Mov Disord 2005; 20:1343.
          </a>
         </li>
         <li class="breakAll">
          Miyasaki J. Unpublished data, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Univeristy of Toronto.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia KP, Schneider SA. Psychogenic tremor and related disorders. J Neurol 2007; 254:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeon A, Ahlskog JE, Bower JH, et al. Psychogenic tremor: long-term prognosis in patients with electrophysiologically confirmed disease. Mov Disord 2009; 24:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidstone SC, Costa-Parke M, Robinson EJ, et al. Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases. J Neurol Neurosurg Psychiatry 2022; 93:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig L, Pasman JA, Nicholson T, et al. Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry 2018; 5:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binzer M, Kullgren G. Motor conversion disorder. A prospective 2- to 5-year follow-up study. Psychosomatics 1998; 39:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein A, Stergiopoulos V, Fine J, Lang AE. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranick S, Ekanayake V, Martinez V, et al. Psychopathology and psychogenic movement disorders. Mov Disord 2011; 26:1844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol 2006; 5:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord 2006; 12:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareés I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. J Neurol Sci 2014; 338:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connell N, Nicholson TR, Wessely S, David AS. Characteristics of patients with motor functional neurological disorder in a large UK mental health service: a case-control study. Psychol Med 2020; 50:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Defazio G, Pastore A, Pellicciari R, et al. Personality disorders and somatization in functional and organic movement disorders. Psychiatry Res 2017; 257:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spagnolo PA, Norato G, Maurer CW, et al. Effects of TPH2 gene variation and childhood trauma on the clinical and circuit-level phenotype of functional movement disorders. J Neurol Neurosurg Psychiatry 2020; 91:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peckham EL, Hallett M. Psychogenic movement disorders. Neurol Clin 2009; 27:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaFaver K, Hallett M. Functional or psychogenic: what's the better name? Mov Disord 2014; 29:1698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon DK, Nishino S, Scammell TE. Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("limp man syndrome"). Mov Disord 2004; 19:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MJ, Stone J, Lang AE. Functional/psychogenic movement disorders: do we know what they are? Mov Disord 2014; 29:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MJ, Fotopoulou A, Pareés I. Neurobiology of functional (psychogenic) movement disorders. Curr Opin Neurol 2013; 26:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MJ, Adams RA, Brown H, et al. A Bayesian account of 'hysteria'. Brain 2012; 135:3495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareés I, Brown H, Nuruki A, et al. Loss of sensory attenuation in patients with functional (psychogenic) movement disorders. Brain 2014; 137:2916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demartini B, Petrochilos P, Ricciardi L, et al. The role of alexithymia in the development of functional motor symptoms (conversion disorder). J Neurol Neurosurg Psychiatry 2014; 85:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newby R, Alty J, Kempster P. Functional dystonia and the borderland between neurology and psychiatry: New concepts. Mov Disord 2016; 31:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer CW, LaFaver K, Ameli R, et al. Impaired self-agency in functional movement disorders: A resting-state fMRI study. Neurology 2016; 87:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallett M, Aybek S, Dworetzky BA, et al. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol 2022; 21:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huys AML, Haggard P, Bhatia KP, Edwards MJ. Misdirected attentional focus in functional tremor. Brain 2021; 144:3436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer CW, LaFaver K, Limachia GS, et al. Gray matter differences in patients with functional movement disorders. Neurology 2018; 91:e1870.
          </a>
         </li>
         <li class="breakAll">
          Suchowersky O, 2006, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MJ, Bhatia KP, Cordivari C. Immediate response to botulinum toxin injections in patients with fixed dystonia. Mov Disord 2011; 26:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas M, Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs 2004; 18:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deuschl G, Köster B, Lücking CH, Scheidt C. Diagnostic and pathophysiological aspects of psychogenic tremors. Mov Disord 1998; 13:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidstone SC, Lang AE. How Do I Examine Patients With Functional Tremor? Mov Disord Clin Pract 2020; 7:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simons RC. The resolution of the Latah paradox. J Nerv Ment Dis 1980; 168:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JE, Maurer CW, Hallett M. The "Whack-a-Mole" Sign in Functional Movement Disorders. Mov Disord Clin Pract 2015; 2:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown P, Rothwell JC, Thompson PD, et al. The hyperekplexias and their relationship to the normal startle reflex. Brain 1991; 114 ( Pt 4):1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Stouwe AM, Elting JW, van der Hoeven JH, et al. How typical are 'typical' tremor characteristics? Sensitivity and specificity of five tremor phenomena. Parkinsonism Relat Disord 2016; 30:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sa DS, Mailis-Gagnon A, Nicholson K, Lang AE. Posttraumatic painful torticollis. Mov Disord 2003; 18:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawley JS, Weiner WJ. Psychogenic dystonia and peripheral trauma. Neurology 2011; 77:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarsy D. Comparison of acute- and delayed-onset posttraumatic cervical dystonia. Mov Disord 1998; 13:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia KP, Bhatt MH, Marsden CD. The causalgia-dystonia syndrome. Brain 1993; 116 ( Pt 4):843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE, Chen R. Dystonia in complex regional pain syndrome type I. Ann Neurol 2010; 67:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majumdar A, López-Casas J, Poo P, et al. Syndrome of fixed dystonia in adolescents--short term outcome in 4 cases. Eur J Paediatr Neurol 2009; 13:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998; 65:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord 2001; 16:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner WJ. Can peripheral trauma induce dystonia? No! Mov Disord 2001; 16:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll CG, Hawley JS, Ney JP. Post-traumatic shoulder dystonia in an active duty soldier. Mil Med 2006; 171:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohlhalter S, Leon-Sarmiento FE, Hallett M. Abnormality of motor cortex excitability in peripherally induced dystonia. Mov Disord 2007; 22:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar H, Jog M. Peripheral trauma induced dystonia or post-traumatic syndrome? Can J Neurol Sci 2011; 38:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munts AG, Koehler PJ. How psychogenic is dystonia? Views from past to present. Brain 2010; 133:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rooijen DE, Geraedts EJ, Marinus J, et al. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry 2011; 82:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fasano A, Valadas A, Bhatia KP, et al. Psychogenic facial movement disorders: clinical features and associated conditions. Mov Disord 2012; 27:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanaan RAA, Duncan R, Goldstein LH, et al. Are psychogenic non-epileptic seizures just another symptom of conversion disorder? J Neurol Neurosurg Psychiatry 2017; 88:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baik JS, Lang AE. Gait abnormalities in psychogenic movement disorders. Mov Disord 2007; 22:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lempert T, Brandt T, Dieterich M, Huppert D. How to identify psychogenic disorders of stance and gait. A video study in 37 patients. J Neurol 1991; 238:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okun MS, Koehler PJ. Paul Blocq and (psychogenic) astasia abasia. Mov Disord 2007; 22:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudarsky L. Psychogenic gait disorders. Semin Neurol 2006; 26:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keane JR. Hysterical gait disorders: 60 cases. Neurology 1989; 39:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993; 43:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidstone SC, Araújo R, Stone J, Bloem BR. Ten myths about functional neurological disorder. Eur J Neurol 2020; 27:e62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daum C, Gheorghita F, Spatola M, et al. Interobserver agreement and validity of bedside 'positive signs' for functional weakness, sensory and gait disorders in conversion disorder: a pilot study. J Neurol Neurosurg Psychiatry 2015; 86:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laub HN, Dwivedi AK, Revilla FJ, et al. Diagnostic performance of the "Huffing and Puffing" sign in psychogenic (functional) movement disorders. Mov Disord Clin Pract 2015; 2:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordbru AA, Smedstad LM, Moen VP, Martinsen EW. Identifying patterns of psychogenic gait by video-recording. J Rehabil Med 2012; 44:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okun MS, Rodriguez RL, Foote KD, Fernandez HH. The "chair test" to aid in the diagnosis of psychogenic gait disorders. Neurologist 2007; 13:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nonnekes J, Růžička E, Serranová T, et al. Functional gait disorders: A sign-based approach. Neurology 2020; 94:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Salm SM, Erro R, Cordivari C, et al. Propriospinal myoclonus: clinical reappraisal and review of literature. Neurology 2014; 83:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monday K, Jankovic J. Psychogenic myoclonus. Neurology 1993; 43:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benaderette S, Zanotti Fregonara P, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord 2006; 21:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyasaki JM, Sa DS, Galvez-Jimenez N, Lang AE. Psychogenic movement disorders. Can J Neurol Sci 2003; 30 Suppl 1:S94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995; 52:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry 2011; 82:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onofrj M, Bonanni L, Manzoli L, Thomas A. Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. Neurology 2010; 74:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallett M. Psychogenic parkinsonism. J Neurol Sci 2011; 310:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demartini B, Ricciardi L, Parees I, et al. A positive diagnosis of functional (psychogenic) tics. Eur J Neurol 2015; 22:527.
          </a>
         </li>
         <li class="breakAll">
          Lang AE. General overview of psychogenic movement disorders: Epidemiology, diagnosis, and prognosis. In: Psychogenic Movement Disorders; Neurology and Neuropsychiatry, Hallet M, Fahn S, Jankovic J, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.35.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pringsheim T, Ganos C, McGuire JF, et al. Rapid Onset Functional Tic-Like Behaviors in Young Females During the COVID-19 Pandemic. Mov Disord 2021; 36:2707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Vahl KR, Edwards MJ. Mind the Difference Between Primary Tics and Functional Tic-like Behaviors. Mov Disord 2021; 36:2716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Vahl KR, Pisarenko A, Jakubovski E, Fremer C. Stop that! It's not Tourette's but a new type of mass sociogenic illness. Brain 2022; 145:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aybek S, Lidstone SC, Nielsen G, et al. What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. J Neuropsychiatry Clin Neurosci 2020; 32:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganos C, Aguirregomozcorta M, Batla A, et al. Psychogenic paroxysmal movement disorders--clinical features and diagnostic clues. Parkinsonism Relat Disord 2014; 20:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. "Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord 2014; 29:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Salm SM, van Rootselaar AF, Cath DC, et al. Clinical decision-making in functional and hyperkinetic movement disorders. Neurology 2017; 88:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2009; 22:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE, Voon V. Psychogenic movement disorders: past developments, current status, and future directions. Mov Disord 2011; 26:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone J, Smyth R, Carson A, et al. Systematic review of misdiagnosis of conversion symptoms and "hysteria". BMJ 2005; 331:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voon V, Lang AE, Hallett M. Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice? Nat Clin Pract Neurol 2007; 3:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frasca Polara G, Fleury V, Stone J, et al. Prevalence of functional (psychogenic) parkinsonism in two Swiss movement disorders clinics and review of the literature. J Neurol Sci 2018; 387:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAuley J, Rothwell J. Identification of psychogenic, dystonic, and other organic tremors by a coherence entrainment test. Mov Disord 2004; 19:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallett M. Physiology of psychogenic movement disorders. J Clin Neurosci 2010; 17:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raethjen J, Kopper F, Govindan RB, et al. Two different pathogenetic mechanisms in psychogenic tremor. Neurology 2004; 63:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwingenschuh P, Katschnig P, Seiler S, et al. Moving toward "laboratory-supported" criteria for psychogenic tremor. Mov Disord 2011; 26:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwingenschuh P, Saifee TA, Katschnig-Winter P, et al. Validation of "laboratory-supported" criteria for functional (psychogenic) tremor. Mov Disord 2016; 31:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Suilleabhain PE, Matsumoto JY. Time-frequency analysis of tremors. Brain 1998; 121 ( Pt 11):2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson PD, Colebatch JG, Brown P, et al. Voluntary stimulus-sensitive jerks and jumps mimicking myoclonus or pathological startle syndromes. Mov Disord 1992; 7:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown P, Thompson PD. Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor. Mov Disord 2001; 16:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibasaki H, Hallett M. What is the Bereitschaftspotential? Clin Neurophysiol 2006; 117:2341.
          </a>
         </li>
         <li class="breakAll">
          Stepped care for functional neurological symptoms. Healthcare Improvement Scotland. NHS Scotland. Available at: http://healthcareimprovementscotland.org/idoc.ashx?docid=6d302668-ff12-4f53-b547-72c19531e37a&amp;version=-1 (Accessed on November 05, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaFaver K, LaFrance WC, Price ME, et al. Treatment of functional neurological disorder: current state, future directions, and a research agenda. CNS Spectr 2020; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology 2012; 79:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espay AJ, Edwards MJ, Oggioni GD, et al. Tremor retrainment as therapeutic strategy in psychogenic (functional) tremor. Parkinsonism Relat Disord 2014; 20:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry 2015; 86:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson C, Edwards MJ, Carson AJ, et al. Occupational therapy consensus recommendations for functional neurological disorder. J Neurol Neurosurg Psychiatry 2020; 91:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker J, Barnett C, Cavalli L, et al. Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy. J Neurol Neurosurg Psychiatry 2021; 92:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MJ, Stone J, Nielsen G. Physiotherapists and patients with functional (psychogenic) motor symptoms: a survey of attitudes and interest. J Neurol Neurosurg Psychiatry 2012; 83:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czarnecki K, Thompson JM, Seime R, et al. Functional movement disorders: successful treatment with a physical therapy rehabilitation protocol. Parkinsonism Relat Disord 2012; 18:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordbru AA, Smedstad LM, Klungsøyr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med 2014; 46:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen G, Ricciardi L, Demartini B, et al. Outcomes of a 5-day physiotherapy programme for functional (psychogenic) motor disorders. J Neurol 2015; 262:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen G, Buszewicz M, Stevenson F, et al. Randomised feasibility study of physiotherapy for patients with functional motor symptoms. J Neurol Neurosurg Psychiatry 2017; 88:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidstone SC, MacGillivray L, Lang AE. Integrated Therapy for Functional Movement Disorders: Time for a Change. Mov Disord Clin Pract 2020; 7:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidstone SC, Nassif W, Juncos J, et al. Diagnosing functional neurological disorder: seeing the whole picture. CNS Spectr 2020; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry 2005; 66:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricciardi L, Edwards MJ. Treatment of functional (psychogenic) movement disorders. Neurotherapeutics 2014; 11:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro AP, Teasell RW. Behavioural interventions in the rehabilitation of acute v. chronic non-organic (conversion/factitious) motor disorders. Br J Psychiatry 2004; 185:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vizcarra JA, Lopez-Castellanos JR, Dwivedi AK, et al. OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. Parkinsonism Relat Disord 2019; 63:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espay AJ, Ries S, Maloney T, et al. Clinical and neural responses to cognitive behavioral therapy for functional tremor. Neurology 2019; 93:e1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinson VK, Weinstein S, Bernard B, et al. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord 2006; 12:177.
          </a>
         </li>
         <li class="breakAll">
          Rosebush P, Mazurek M. Treatment of conversion disorder. In: Psychogenic Movement Disorders, Hallett M, Fahn S, Jankovic J, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.289.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob AE, Kaelin DL, Roach AR, et al. Motor Retraining (MoRe) for Functional Movement Disorders: Outcomes From a 1-Week Multidisciplinary Rehabilitation Program. PM R 2018; 10:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack R, Moriarty J, Mellers JD, et al. Specialist inpatient treatment for severe motor conversion disorder: a retrospective comparative study. J Neurol Neurosurg Psychiatry 2014; 85:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saifee TA, Kassavetis P, Pareés I, et al. Inpatient treatment of functional motor symptoms: a long-term follow-up study. J Neurol 2012; 259:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demartini B, Batla A, Petrochilos P, et al. Multidisciplinary treatment for functional neurological symptoms: a prospective study. J Neurol 2014; 261:2370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oriuwa C, Mollica A, Feinstein A, et al. Neuromodulation for the treatment of functional neurological disorder and somatic symptom disorder: a systematic review. J Neurol Neurosurg Psychiatry 2022; 93:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moene FC, Spinhoven P, Hoogduin KA, van Dyck R. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. Int J Clin Exp Hypn 2003; 51:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry 2014; 85:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim NM, Martino D, van de Warrenburg BP, et al. The prognosis of fixed dystonia: a follow-up study. Parkinsonism Relat Disord 2009; 15:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YJ, Pakiam AS, Lang AE. Historical and clinical features of psychogenic tremor: a review of 70 cases. Can J Neurol Sci 1999; 26:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr 2006; 11:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson A, Stone J, Hibberd C, et al. Disability, distress and unemployment in neurology outpatients with symptoms 'unexplained by organic disease'. J Neurol Neurosurg Psychiatry 2011; 82:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson AJ, Ringbauer B, Stone J, et al. Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics. J Neurol Neurosurg Psychiatry 2000; 68:207.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14132 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, American Psychiatric Association, Arlington 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630495" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : What should we call pseudoseizures? The patient's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630495" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : What should we call pseudoseizures? The patient's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7872143" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Phenomenology and psychopathology related to psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7561921" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Psychogenic movement disorders: frequency, clinical profile, and characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759366" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Psychogenic movement disorders in children: a report of 15 cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30191082" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical Characteristics of Functional Movement Disorders: A Clinic-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342362" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The syndrome of fixed dystonia: an evaluation of 103 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14738942" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Psychogenic movement disorders in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31413900" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Functional Movement Disorders in Elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23418043" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Functional movement disorders are not uncommon in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32778007" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A Review and Expert Opinion on the Neuropsychiatric Assessment of Motor Functional Neurological Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23620449" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence and 12-month outcome of non-transient childhood conversion disorder in the U.K. and Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33104173" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33163563" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16001406" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Transcultural comparison of psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16001406" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Transcultural comparison of psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17417745" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Psychogenic tremor and related disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18831532" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Psychogenic tremor: long-term prognosis in patients with electrophysiologically confirmed disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35217516" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526521" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9819952" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Motor conversion disorder. A prospective 2- to 5-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11513100" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714007" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Psychopathology and psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16857575" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16737838" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long-term prognosis of patients with psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24439198" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Physical precipitating factors in functional movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30773149" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Characteristics of patients with motor functional neurological disorder in a large UK mental health service: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780279" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Personality disorders and somatization in functional and organic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32576619" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of TPH2 gene variation and childhood trauma on the clinical and circuit-level phenotype of functional movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19555832" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25242623" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Functional or psychogenic: what's the better name?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15254948" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("limp man syndrome").
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25284581" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Functional/psychogenic movement disorders: do we know what they are?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23823467" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neurobiology of functional (psychogenic) movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22641838" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A Bayesian account of 'hysteria'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25161293" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Loss of sensory attenuation in patients with functional (psychogenic) movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24610939" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The role of alexithymia in the development of functional motor symptoms (conversion disorder).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27753149" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Functional dystonia and the borderland between neurology and psychiatry: New concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27385746" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Impaired self-agency in functional movement disorders: A resting-state fMRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35430029" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Functional neurological disorder: new subtypes and shared mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34145898" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Misdirected attentional focus in functional tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30305450" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Gray matter differences in patients with functional movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30305450" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gray matter differences in patients with functional movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21394784" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immediate response to botulinum toxin injections in patients with fixed dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15139799" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Psychogenic movement disorders: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9539344" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Diagnostic and pathophysiological aspects of psychogenic tremors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32626816" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : How Do I Examine Patients With Functional Tremor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7365478" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The resolution of the Latah paradox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30838230" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The "Whack-a-Mole" Sign in Functional Movement Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1884185" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The hyperekplexias and their relationship to the normal startle reflex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27346607" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : How typical are 'typical' tremor characteristics? Sensitivity and specificity of five tremor phenomena.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14673885" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Posttraumatic painful torticollis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810699" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Psychogenic dystonia and peripheral trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9613741" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comparison of acute- and delayed-onset posttraumatic cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8353711" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The causalgia-dystonia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20373359" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Dystonia in complex regional pain syndrome type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18996036" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Syndrome of fixed dystonia in adolescents--short term outcome in 4 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9810945" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Peripherally induced oromandibular dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11215595" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Can peripheral trauma induce dystonia and other movement disorders? Yes!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11215572" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Can peripheral trauma induce dystonia? No!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16808127" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Post-traumatic shoulder dystonia in an active duty soldier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17415790" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Abnormality of motor cortex excitability in peripherally induced dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21156425" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Peripheral trauma induced dystonia or post-traumatic syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20350935" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : How psychogenic is dystonia? Views from past to present.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21493756" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Peripheral trauma and movement disorders: a systematic review of reported cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23033125" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Psychogenic facial movement disorders: clinical features and associated conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28235779" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Are psychogenic non-epileptic seizures just another symptom of conversion disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17216648" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Gait abnormalities in psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1869889" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : How to identify psychogenic disorders of stance and gait. A video study in 37 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516452" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Paul Blocq and (psychogenic) astasia abasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16791781" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Psychogenic gait disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2927686" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hysterical gait disorders: 60 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8437689" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Human walking and higher-level gait disorders, particularly in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32400011" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Ten myths about functional neurological disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24994927" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Interobserver agreement and validity of bedside 'positive signs' for functional weakness, sensory and gait disorders in conversion disorder: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25961068" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Diagnostic performance of the "Huffing and Puffing" sign in psychogenic (functional) movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22124565" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Identifying patterns of psychogenic gait by video-recording.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17351529" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The "chair test" to aid in the diagnosis of psychogenic gait disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32482839" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Functional gait disorders: A sign-based approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25305154" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Propriospinal myoclonus: clinical reappraisal and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8437701" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Psychogenic myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16211590" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691482" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7639632" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Psychogenic parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21933950" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Diagnosis and treatment of psychogenic parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20479358" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21458829" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Psychogenic parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20019219" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The role of DAT-SPECT in movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25487253" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A positive diagnosis of functional (psychogenic) tics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25487253" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A positive diagnosis of functional (psychogenic) tics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34387394" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Rapid Onset Functional Tic-Like Behaviors in Young Females During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34921458" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Mind the Difference Between Primary Tics and Functional Tic-like Behaviors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34424292" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Stop that! It's not Tourette's but a new type of mass sociogenic illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31587627" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24090947" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Psychogenic paroxysmal movement disorders--clinical features and diagnostic clues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25255973" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : "Psychogenic" versus "functional" movement disorders? That is the question.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913700" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Clinical decision-making in functional and hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19542886" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21626561" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Psychogenic movement disorders: past developments, current status, and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16223792" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Systematic review of misdiagnosis of conversion symptoms and "hysteria".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262077" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29571869" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Prevalence of functional (psychogenic) parkinsonism in two Swiss movement disorders clinics and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15022179" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Identification of psychogenic, dystonic, and other organic tremors by a coherence entrainment test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20493708" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Physiology of psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365128" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Two different pathogenetic mechanisms in psychogenic tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956485" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Moving toward "laboratory-supported" criteria for psychogenic tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26879346" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Validation of "laboratory-supported" criteria for functional (psychogenic) tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827772" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Time-frequency analysis of tremors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1620144" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Voluntary stimulus-sensitive jerks and jumps mimicking myoclonus or pathological startle syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11481681" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16876476" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : What is the Bereitschaftspotential?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16876476" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : What is the Bereitschaftspotential?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33280634" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Treatment of functional neurological disorder: current state, future directions, and a research agenda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22764261" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679736" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Tremor retrainment as therapeutic strategy in psychogenic (functional) tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25433033" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Physiotherapy for functional motor disorders: a consensus recommendation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732388" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Occupational therapy consensus recommendations for functional neurological disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34210802" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496582" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Physiotherapists and patients with functional (psychogenic) motor symptoms: a survey of attitudes and interest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22113131" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Functional movement disorders: successful treatment with a physical therapy rehabilitation protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24248149" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25557282" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Outcomes of a 5-day physiotherapy programme for functional (psychogenic) motor disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27694498" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Randomised feasibility study of physiotherapy for patients with functional motor symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32071934" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Integrated Therapy for Functional Movement Disorders: Time for a Change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33161935" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Diagnosing functional neurological disorder: seeing the whole picture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16401153" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Antidepressant treatment outcomes of psychogenic movement disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24356785" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Treatment of functional (psychogenic) movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286065" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Behavioural interventions in the rehabilitation of acute v. chronic non-organic (conversion/factitious) motor disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30777651" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31586023" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Clinical and neural responses to cognitive behavioral therapy for functional tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16364676" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16364676" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29783067" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Motor Retraining (MoRe) for Functional Movement Disorders: Outcomes From a 1-Week Multidisciplinary Rehabilitation Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24124043" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Specialist inpatient treatment for severe motor conversion disorder: a retrospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22584953" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Inpatient treatment of functional motor symptoms: a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239392" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Multidisciplinary treatment for functional neurological symptoms: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35115389" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Neuromodulation for the treatment of functional neurological disorder and somatic symptom disorder: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12825917" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24029543" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The prognosis of functional (psychogenic) motor symptoms: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19442561" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : The prognosis of fixed dystonia: a follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10451741" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Historical and clinical features of psychogenic tremor: a review of 70 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816790" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Psychogenic tremor: long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257981" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Disability, distress and unemployment in neurology outpatients with symptoms 'unexplained by organic disease'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10644789" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Do medically unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology outpatient clinics.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
